Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Total Voting Rights

1 Feb 2019 07:00

RNS Number : 7519O
Futura Medical PLC
01 February 2019
 

 

 

Futura Medical plc

("Futura" or "the Company")

Total Voting Rights

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,660,267 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,660,267 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

For media enquiries please contact:

 

 

Futura Medical plc

Optimum Strategic Communications

Angela Hildreth, FD/COO

Mary Clark/ Hollie Vile/ Ellie Blackwell

investor.relations@futuramedical.com

Email: futuramedical@optimumcomms.com

www.futuramedical.com

Tel: +44 (0) 203 950 9144

Tel: +44 (0) 1483 685 670

 

 

 

Nominated Advisor/Broker

 

N+1 Singer

 

Aubrey Powell/ Ben Farrow (Corporate Finance)

 

Tom Salvesen/ Mia Gardner (Corporate Broking)

 

Tel: +44 (0) 20 7496 3000

 

 

Notes to Editors

 

Futura Medical plc

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRZMGFMNMVGLZM
Date   Source Headline
4th Jun 20267:00 amRNSNotice of AGM & availability of Annual Report
1st Jun 20263:30 pmRNSBlock Listing Six Monthly Return
22nd May 202612:06 pmRNSHolding(s) in Company
29th Apr 20267:00 amRNSUnaudited Results for the Year Ended 31 Dec 2025
20th Apr 20267:00 amRNSNotice of Results & Investor Presentation
23rd Mar 20267:00 amRNSPositive Eroxon® & Eroxon® “Intense” HUT results
18th Mar 20267:00 amRNSFormal Grant of US Patent
17th Mar 202611:37 amRNSHolding(s) in Company
20th Feb 20264:06 pmRNSHolding(s) in Company
5th Feb 20267:00 amRNSPatent notice of allowance granted for the US
4th Feb 20267:00 amRNSTrading Update
13th Jan 202612:53 pmRNSHolding(s) in Company
13th Jan 202612:51 pmRNSHolding(s) in Company
12th Jan 20267:00 amRNSResults of WSD4000 Early Feasibility Study
7th Jan 20264:34 pmRNSNotification of major holdings
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 20255:31 pmRNSNotification of major holdings
30th Dec 20255:31 pmRNSNotification of major holdings
23rd Dec 20254:37 pmRNSNotification of major holdings
23rd Dec 20254:37 pmRNSNotification of major holdings
18th Dec 20256:15 pmRNSNotification of major holdings
18th Dec 20256:15 pmRNSNotification of major holdings
18th Dec 20255:41 pmRNSNotification of major holdings
18th Dec 20255:41 pmRNSNotification of major holdings
12th Dec 20254:18 pmRNSNotification of major holdings
10th Dec 202512:01 pmRNSNotification of major holdings
10th Dec 202512:00 pmRNSNotification of major holdings
10th Dec 20257:00 amRNSPatent notice of allowance granted for China
9th Dec 20253:59 pmRNSBlock Listing Six Monthly Return
8th Dec 20251:34 pmRNSNotification of major holdings
8th Dec 202512:18 pmRNSDirectors' / PDMR dealing
4th Dec 20253:43 pmRNSNotification of major holdings
4th Dec 20253:41 pmRNSNotification of major holdings
3rd Dec 20257:00 amRNSBoard change
2nd Dec 202511:27 amRNSResult of General Meeting and Total Voting Rights
14th Nov 20254:40 pmRNSPCA Dealing
13th Nov 20254:35 pmRNSPosting of Circular and Notice of GM
13th Nov 20257:00 amRNSFundraise of £2.75 million
3rd Nov 202511:04 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSResults for the six months ended 30 June 2025
26th Sep 202512:11 pmRNSNotice of Results and Investor Presentation
19th Sep 20257:00 amRNSTrading, Business and Strategic Review Update
29th Aug 20257:00 amRNSTotal Voting Rights
8th Aug 20257:00 amRNSBoard Changes, Business Update & Notice of Results
11th Jul 202511:04 amRNSShare price movement
8th Jul 20257:00 amRNSBoard Changes
20th Jun 20257:00 amRNSResult of AGM
2nd Jun 20253:15 pmRNSBlock Listing Six Monthly Return
27th May 20257:00 amRNSNotice of AGM and availability of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.